Literature DB >> 16598778

Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein.

Fei Li1, Ning Wu, Rui-Bin Su, Jian-Quan Zheng, Bo Xu, Xin-Qiang Lu, Bin Cong, Jin Li.   

Abstract

Imidazoline receptor antisera-selected protein (IRAS) is considered as a candidate for the I1-imidazoline receptor (I1R), but the signaling pathway mediated by IRAS remains unknown. In our study, the signal transduction pathways of IRAS were investigated in CHO cells stably expressing IRAS (CHO-IRAS), and compared to the native I1R signaling pathways. Rilmenidine or moxonidine (10 nM-100 microM), I1R agonists, failed to stimulate [35S]-GTPgammaS binding in CHO-IRAS cell membrane preparations, suggesting that G protein may not be involved in IRAS signaling pathway. However, incubation of CHO-IRAS with rilmenidine or moxonidine for 5 min could induce an upregulation of phosphatidylcholine-selective phospholipase C (PC-PLC) activity, and an increase in the accumulation of diacylglycerol (DAG), the hydrolysate of PC-PLC, in a concentration-dependent manner. The elevated activation of PC-PLC by rilmenidine or moxonidine (100 nM) could be blocked by efaroxan, a selective I1R antagonist. Cells treated with rilmenidine or moxonidine showed an increased level of extracellular signal-regulated kinase (ERK) phosphorylation in a concentration-dependent manner, which could be reversed by efaroxan or D609, a selective PC-PLC inhibitor. These results suggest that the signaling pathway of IRAS in response to I1R agonists coupled with the activation of PC-PLC and its downstream signal transduction molecule, ERK. These findings are similar to those in the signaling pathways of native I1R, providing some new evidence for the relationship between I1R and IRAS. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598778     DOI: 10.1002/jcb.20806

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  The antiarrhythmic effect of centrally administered rilmenidine involves muscarinic receptors, protein kinase C and mitochondrial signalling pathways.

Authors:  M Iwasaki; Y Hayashi; T Kamibayashi; A Yamatodani; T Mashimo
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

2.  Silica induces macrophage cytokines through phosphatidylcholine-specific phospholipase C with hydrogen peroxide.

Authors:  Honglei Liu; Hongqiao Zhang; Henry Jay Forman
Journal:  Am J Respir Cell Mol Biol       Date:  2006-12-07       Impact factor: 6.914

3.  Platelet imidazoline receptors as state marker of depressive symptomatology.

Authors:  John Piletz; Robert Baker; Angelos Halaris
Journal:  J Psychiatr Res       Date:  2006-12-12       Impact factor: 4.791

4.  Facilitation of central imidazoline I(1)-site/extracellular signal-regulated kinase/p38 mitogen-activated protein kinase signalling mediates the hypotensive effect of ethanol in rats with acute renal failure.

Authors:  Mahmoud M El-Mas; Hanan M El-Gowelli; Abdel-Rheem M Ghazal; Osama F Harraz; Mahmoud M Mohy El-Din
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

5.  Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1/2 production in the rostral ventrolateral medulla of rats.

Authors:  Jian Zhang; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2007-10-16       Impact factor: 4.030

Review 6.  Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence.

Authors:  Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2007-07-25       Impact factor: 5.046

Review 7.  Role of Nischarin in the pathology of diseases: a special emphasis on breast cancer.

Authors:  Samuel C Okpechi; Hassan Yousefi; Khoa Nguyen; Thomas Cheng; Nikhilesh V Alahari; Bridgette Collins-Burow; Matthew E Burow; Suresh K Alahari
Journal:  Oncogene       Date:  2022-01-22       Impact factor: 9.867

8.  Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted Therapy.

Authors:  Franca Podo; Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Carlo Ramoni; Alessandro Ricci; Maria Elena Pisanu; Francesco Sardanelli; Rossella Canese; Egidio Iorio
Journal:  Front Oncol       Date:  2016-08-02       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.